Portal de Periódicos da CAPES

Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancera

1995; Wiley; Volume: 761; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1995.tb31376.x

1749-6632

Robert I. Nicholson, Julia M.W. Gee, David L. Manning, A. E. Wakeling, Monica M. Montano, Benita S. Katzenellenbogen,

Gene expression and cancer classification

Annals of the New York Academy of SciencesVolume 761, Issue 1 p. 148-163 Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen-Sensitive and-Resistant Experimental and Clinical Breast Cancera R. I. NICHOLSON, R. I. NICHOLSON Tenovus Cancer Research Centre University of Wales College of Medicine Tenovus Building Heath Park Cardiff CF4 4XX, United KingdomSearch for more papers by this authorJ. M. W. GEE, J. M. W. GEE Tenovus Cancer Research Centre University of Wales College of Medicine Tenovus Building Heath Park Cardiff CF4 4XX, United KingdomSearch for more papers by this authorD. L. MANNING, D. L. MANNING Tenovus Cancer Research Centre University of Wales College of Medicine Tenovus Building Heath Park Cardiff CF4 4XX, United KingdomSearch for more papers by this authorA. E. WAKELING, A. E. WAKELING Zeneca Pharmaceuticals Macclesfield, United KingdomSearch for more papers by this authorM. M. MONTANO, M. M. MONTANO Department of Physiology and Biophysics University of Illinois Urbana, IllinoisSearch for more papers by this authorB. S. KATZENELLENBOGEN, B. S. KATZENELLENBOGEN Department of Physiology and Biophysics University of Illinois Urbana, IllinoisSearch for more papers by this author R. I. NICHOLSON, R. I. NICHOLSON Tenovus Cancer Research Centre University of Wales College of Medicine Tenovus Building Heath Park Cardiff CF4 4XX, United KingdomSearch for more papers by this authorJ. M. W. GEE, J. M. W. GEE Tenovus Cancer Research Centre University of Wales College of Medicine Tenovus Building Heath Park Cardiff CF4 4XX, United KingdomSearch for more papers by this authorD. L. MANNING, D. L. MANNING Tenovus Cancer Research Centre University of Wales College of Medicine Tenovus Building Heath Park Cardiff CF4 4XX, United KingdomSearch for more papers by this authorA. E. WAKELING, A. E. WAKELING Zeneca Pharmaceuticals Macclesfield, United KingdomSearch for more papers by this authorM. M. MONTANO, M. M. MONTANO Department of Physiology and Biophysics University of Illinois Urbana, IllinoisSearch for more papers by this authorB. S. KATZENELLENBOGEN, B. S. KATZENELLENBOGEN Department of Physiology and Biophysics University of Illinois Urbana, IllinoisSearch for more papers by this author First published: June 1995 https://doi.org/10.1111/j.1749-6632.1995.tb31376.xCitations: 64 a The authors gratefully acknowledge the financial support of the Tenovus Organisation (RIN, JMWG, DLM), the Association for International Breast Cancer Research (RIN), the National Institutes of Health, and the Susan G. Komen Foundation (BSK). AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Wakeling, A. E. 1993. The future of pure antioestrogens in clinical breast cancer. Br. Cancer Res. Treat. 25: 1–9. 2 Nicholson, R. I., A. B. Francis, D. L. Manning & J. M. W. Gee 1994. Pure antioestrogens (ICI164384 and ICI 182780) and breast cancer: Is the attainment of complete oestrogen withdrawal worthwhile Endocrine-Related Cancer 1(4): 5–17. 3 Wilson, A. P. M., P. J. Weatherill, R. I. Nicholson, P. Daves & A. E. Wakeling 1990. A comparative study of the interaction of oestradiol and the steroidal pure antioestrogen, ICI 164384 with molybdate stabilized oestrogen receptor. J. Steroid Biochem. 35: 421–428. 4 Wakeling, A. E. & J. Bowler 1987. Steroidal pure antioestrogens. J. Endocrinol. 112: R7–R10. 5 Nicholson, R. I., J. M. W. Gee, C. L. Eaton, D. L. Manning, R. E. Mansel, A. K. Sharma, A. Douglas-Jones, M. Price-Thomas, A. Howell, D. J. Defriend, N. J. Bundred, E. Anderson, J. F. R. Robertson, R. W. Blamey, M. Dowsett, P. Walton & A. E. Wakeling 1994. Pure antioestrogens in breast cancer: experimental and clinical observations. In Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Excerpta Medica International Congress Series. M. Motta & M. Serio, Eds. 347–360. Elsevier Science B. V. Amsterdam . 6 Defriend, D. L., A. Howell, R. I. Nicholson, E. Anderson, M. Dowsett, R. E. Mansel, R. W. Blamey, N. J. Bundred, J. R. Robertson, C. Saunders, M. Baum, P. Walton, F. Sutcliffe & A. E. Wakeling 1994. Investigation of a new pure antioestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 54: 1–7. 7 Howell, A., D. L. Defriend, R. W. Blamey, J. F. Robertson & P. Walton Response to a pure antioestrogen (ZM 182780) in tamoxifen resistant breast cancer. Lancet. In press. 8 Musgrove, E. A., A. E. Wakeling & R. L. Sutherland 1989. Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res. 49: 2398–2404. 9 Wakeling, A. E., E. Newboult & S. W. Peters 1989. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J. Mol. Endocrinol. 2: 225–234. 10 Nicholson, R. I., K. J. Walker, N. Bouzubar, R. Wills, J. M. W. Gee, N. K. Rushmere & P. Daves 1990. Estrogen deprivation in breast cancer: clinical, experimental and biological aspects. Ann. N. Y. Acad. Sci. 595: 316–327. 11 Wiseman, L. R., A. E. Wakeling, F. E. May & B. R. Westley 1989. Effects of the antioestrogen, ICI 164384, on oestrogen induced mRNAs in MCF-7 cells. J. Steroid Biochem. 31: 1–6. 12 Lykkesfeldt, A. E. & E. K. Sorensen 1992. Effect of estrogen and antioestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol. 31: 131–138. 13 Lykkesfeldt, A. E., M. W. Madsen & P. Briand 1994. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164384 and ICI 182780 sensitive human breast cancer cell line, MCF-7/TAMR-l. Cancer Res. 54: 1587–1595. 14 Manning, D. L., R. A. McClelland, S. Bryant, J. Knowlden, J. M. W. Gee, A. B. Francis, J. F. R. Robertson, R. W. Blamey, R. L. Sutherland, C J. Ormandy, R. E. Mansel & R. I. Nicholson Oestrogen regulated genes in breast cancer: role in prognosis and endocrine sensitivity. Acta Oncol. In press. 15 Manning, D. L. & R. I. Nicholson 1993. Isolation of pMGTl: a gene that is repressed by oestrogen and increased by antioestrogens and antioprogestins. Eur. J. Cancer 29A: 759–762. 16 Bates, S. E., N. E. Davidson, E. V. Valverius, C. E. Freter, R. B. Dickson, J. P. Tam, J. E. Kudlow, M. E. Lippman & D. S. Solomon 1988. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by oestradiol and its possible functional significance. Mol. Endocrinol. 2: 543–555. 17 Gee, J. M. W., J. F. R. Robertson, H. B. Hoyle, S. R. Kyme, R. A. McClelland, I. O. Ellis, R. W. Blamey & R. I. Nicholson 1994. Immunocytochemical localisation of BCL-2 protein in human breast cancer and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer. 59: 619–628. 18 Bouzubar, N., K. J. Walker, K. Griffiths, I. O. Ellis, C. W. Elston, J. Robertson, R. W. Blamey & R. I. Nicholson 1989. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br. J. Cancer 59: 943–947. 19 Press, M. F. & G. L. Greene 1988. Immunocytochemical localisation of oestrogen and progesterone receptors. In Advances in Immunohistochemistry. R. A. DeLellis, Ed. 341–361. Raven Press. New York . 20 Bouzubar, N. F. H. 1991. Studies on hormone and antihormone action in early breast cancer using immunocytochemical techniques. PhD Thesis. University of Wales College of Medicine. Cardiff . 21 Wakeling, A. E. & J. Bowler 1988. Novel antioestrogens without partial agonistic activity. J. Steroid Biochem. 31: 645–653. 22 Wakeling, A. E., M. Dukes & J. Bowler 1991. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51: 3867–3873. 23 Nicholson, R. I. 1992. Pure antioestrogens and breast cancer. In Current Directions in Cancer Chemotherapy. IBC Technical Services. London . 24 Gibson, M. K., L. A. Nemmers, L. A. Beckman, W. C. Beckman, V. L. Davis, S. W. Curtis & K. S. Korach 1991. The mechanism of ICI164384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000–2010. 25 Dauvois, S., P. S. Danielian, R. White & M. G. Parker 1992. Antiestrogen ICI 164384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. USA 89: 4037–4041. 26 Fawell, S. E., R. White, S. Hoare, M. Sydenham, M. Page & M. G. Parker 1990. Inhibition of estrogen receptor-DNA binding by the pure antioestrogen ICI 164384 appears to be mediated by impaired receptor dimerisation. Proc. Natl. Acad. Sci. USA 87: 6883–6887. 27 Eckert, R. L., A. Mullick, E. A. Rorke & B. S. Katzenellenbogen 1984. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology 114: 629–637. 28 Pasqualini, J. R., B. Schatz, C. Vartn & B. L. Nguyen 1992. Recent data on estrogen sulfatases and sulphotransferases activities in human breast cancer. J. Steroid Biochem. Mol. Biol. 41: 323–329. 29 Santner, S. J., B. Ohlsson-Wilhelm & R. J. Santen 1993. Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. Int. J. Cancer 54: 119–124. 30 Howarth, N. M., A. Purohit, M. J. Reed & B. V. L. Potter 1994. Estrone sulfamates: potential inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 37: 219–221. 31 Chetrite, G., C. Vartn, L. Delalonde & J. R. Pasqualini 1993. Effect of promegestone, tamoxifen, 4-hydrodoxytamoxifen and ICI 164384 on the oestrone sulphatase activity of human breast cancer cells. Anticancer Res. 13: 931–934. 32 Stewart, A. J., M. D. Johnson, F. E. B. May & B. R. Westley 1990. Role of insulin-like growth factors and type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 265: 21172–21178. 33 Stewart, A. J., B. R. Westley, & F. E. B. May 1992. Modulation of proliferative response of breast cancer cells to growth factors by oestrogen. Br. J. Cancer 66: 640–648. 34 Westley, B. R. & F. E. B. May 1991. IGFs and control of cell proliferation in breast and other cancers. Rev. Endocr. Relat. Cancer 39: 29–34. 35 Ignar-Trowbridge, D. M., K. G. Nelson, M. C. Bidwell, S. W. Curtis, T. F. Washburn, J. A. McLachlan & K. S. Korach 1992. Coupling of dual signalling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA 89: 4658–4662. 36 Wakeling, A. E., 1994. Inhibition of EGF-receptor tyrosine kinase activity by 4-aniloquinazolines. Br. J. Cancer 69 (Suppl. XXI): 18, Abstract 6.6. 37 Reddy, K. B., G. L. Mangold, A. K. Tandon, T. Yoneda, G. R. Mundy, A. Zilberstein & C. K. Osborne 1992. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 52: 3636–3641. 38 Power, R. F., S. K. Mani, J. Codina, O. M. Conneelly & B. W. O'Malley 1991. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254: 1636–1639. 39 Nicholson, R. I., R. A. McClelland, J. M. W. Gee, D. L. Manning, P. Cannon, J. F. R. Robertson, I. O. Ellis & R. W. Blamey 1994. Transforming growth factor α and endocrine sensitivity in breast cancer. Cancer Res. 54: 1684–1689. 40 Osborne, C. K., E. B. Coronado & J. P. Robinson 1987. Human breast cancer in the athymic mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol. 23: 1189–1196. 41 Osborne, C. K., M. Jarman, R. McCague, E. B. Coronado, S. G. Hilsenbeck & A. E. Wakeling 1994. The importance of tamoxifen metabolism in tamoxifen-stimulated growth. Cancer Chemother. Pharmacol. 34: 89–95. 42 Gottardis, M. M. & V. C. Jordan 1988. Development of tamoxifen-stimulated growth of MCF-7 tumours in athymic mice after long-term antioestrogen administration. Cancer Res. 48: 5183–5187. 43 Clarke R., N. Brunner, B. S. Katzenellenbogen, E. W. Thompson, M. J. Norman, C. Koppi, S. Pair, M. E. Lippman & R. B. Dickson 1989. Progression of breast cancer cells from hormone dependent to hormone independent growth both in vitro and in vivo. Proc. Natl. Acad. Sci. USA 86: 3649–3653. 44 Graham, M. L., J. A. Smith, P. B. Jewett & K. B. Horwitz 1992. Heterogeneity of progesterone receptor content and remodelling by tamoxifen characterise subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res. 52: 593–602. 45 Brunner, N., B. Boysen, J. F. Kiilgaard, T. L. Fransden, S. Jirus & R. Clarke 1993a. Resistance to 40H-tamoxifen does not confer resistance to the steroidal antioestrogen ICI 182780, while acquired resistance to ICI 182780 results in cross-resistance to 40H-tamoxifen. Breast Cancer Res. Treat. 27: 135. Abstract 19. 46 Bronzert, D. A., G. L. Greene & M. E. Lippman 1985. Selection and characterization of breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 117: 1409–1417. 47 Clarke, R., E. W. Thompson, F. Leonessa, J. Lippman, M. McGarvey, T. L. Frandsen & N. Brunner 1993. Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res. Treat. 24: 227–239. 48 Gottardis, M. M., S.-Y. Jiang, M.-H. Jeng & V. C. Jordan 1989. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumour variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 49: 4090–4093. 49 Osborne, C. K., E. B. Coronado-Heinsohn, B. L. McCue, A. E. Wakeling & R. I. Nicholson Pure steroidal antiestrogens are superior to tamoxifen in a preclinical model of human breast cancer. Submitted. 50 Charpin, C., P. Bonnier, A. Khouzami, H. Vaheret, L. Andrac, M. N. Lavaut, C. Allasia & L. Plana 1992. Inflammatory breast carcinoma: an immunohistochemical study using anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res. 52: 591–597. 51 Walker, K. J., N. Bouzubar, J. Robertson, I. O. Ellis, C. W. Elston, R. W. Blamey, D. W. Wilson, K. Griffiths & R. I. Nicholson 1988. Immunocytochemical localisation of estrogen receptor in human breast cancer. Cancer Res. 48: 6517–6522. 52 Reece, J. C. & B. S. Katzenellenbogen 1992. Examination of the DNA-binding ability of ER in whole cells: implications for hormone independent transactivation and the actions of antioestrogens. Mol. Cell. Biol. 12: 4531–4538. 53 Nicholson, R. I., A. B. Francis, J. M. W. Gee, D. L. Manning, A. E. Wakeling & B. S. Katzenellenbogen Observations arising from the use of pure antioestrogens on oestrogen-Responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells. Rev. Endocr. Relat. Cancer. In press. 54 Katzenellenbogen, B. S., K. L. Kendra, M. J. Norman & Y. Berrthois 1987. Proliferation, hormonal responsiveness and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 47: 4355–4360. 55 Cho, H., P. A. Ng & B. S. Katzenellenbogen 1991. Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines. Mol. Endocrinol. 5: 1323–1330. 56 Nunez, A., M. Berry, J. L. Imler & P. Chambon 1989. The 5′-flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J. 8: 823–829. 57 Howell, A., D. J. Dodwell, I. Laidlaw, H. Anderson & E. Anderson 1990. Tamoxifen as an agonist for metastatic breast cancer. In Endocrine Therapy of Breast Cancer IV. A. Goldhirsch, Ed. 49–58. Springer-Verlag. Berlin . 58 Howell, A., D. J. Dodwell, H. Anderson & J. Redford 1992. Response after withdrawal of tamoxifen and progestins in advanced breast cancer. Ann. Oncol. 3: 611–617. 59 Wilson, A. J. 1983. Response in breast cancer to a second hormonal therapy. Rev. Endocr. Relat. Cancer 14: 5–11. 60 Vogel, C. L., I. Shemano, J. Schoenfelder, P. A. Gams & M. R. Green 1993. Multicenter Phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol. 11: 345–350. 61 Nicholson, R. I. 1993. Recent advances in the antihormonal therapy of breast cancer. Curr. Opin. Invest. Drugs 2: 1259–1268. 62 Nicholson, R. I., D. L. Manning & J. M. W. Gee 1993. New antihormonal approaches to breast cancer therapy. Drugs Today 29: 363–372. Citing Literature Volume761, Issue1Steroid Receptors and AntihormonesJune 1995Pages 148-163 ReferencesRelatedInformation